Advanced in Cholangiocarcinoma (Bile Duct Cancer)

Dr. Kyriakos P. Papadopoulos

Hematology Oncology | Hematology | Oncology
South Texas Oncology And Hematology, PLLC
4383 Medical Dr, 
San Antonio, TX 
Accepting New Patients
Advanced in Cholangiocarcinoma (Bile Duct Cancer)
South Texas Oncology And Hematology, PLLC
4383 Medical Dr, 
San Antonio, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Kyriakos Papadopoulos is a Hematologist Oncology specialist and a Hematologist in San Antonio, Texas. Dr. Papadopoulos is rated as an Advanced provider by MediFind in the treatment of Cholangiocarcinoma (Bile Duct Cancer). His top areas of expertise are Adenoid Cystic Carcinoma, Salivary Gland Tumors, Acute Megakaryoblastic Leukemia, and Breast Cancer. Dr. Papadopoulos is currently accepting new patients.

His clinical research consists of co-authoring 119 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Cholangiocarcinoma (Bile Duct Cancer).

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in TX
Hospital Affiliations
Methodist Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

SOUTH TEXAS ONCOLOGY AND HEMATOLOGY, PLLC
4383 Medical Dr, San Antonio, TX 78229
Other Locations
SOUTH TEXAS ONCOLOGY AND HEMATOLOGY, PLLC
155 E Sonterra Blvd, Suite 200, San Antonio, TX 78258

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Phase 1a/2a Dose Escalation Trial to Determine Safety, Tolerance, MTD, and Preliminary Antineoplastic Activity of AVID100, in Patients With Advanced or Metastatic Solid Tumors of Epithelial Origin
Phase 1a/2a Dose Escalation Trial to Determine Safety, Tolerance, MTD, and Preliminary Antineoplastic Activity of AVID100, in Patients With Advanced or Metastatic Solid Tumors of Epithelial Origin
Enrollment Status: Terminated
Publish Date: June 11, 2025
Intervention Type: Drug
Study Drug: AVID100
Study Phase: Phase 1/Phase 2
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Enrollment Status: Completed
Publish Date: May 03, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1 Study of SY 5609, an Oral, Selective CDK7 Inhibitor, in Adult Patients With Select Advanced Solid Tumors
A Phase 1 Study of SY 5609, an Oral, Selective CDK7 Inhibitor, in Adult Patients With Select Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: October 27, 2023
Intervention Type: Drug
Study Drugs: SY-5609, Fulvestrant
Study Phase: Phase 1
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: February 21, 2023
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1b/2, Open Label, Dose Escalation and Expansion Study of the Glutaminase Inhibitor Telaglenastat (CB-839) in Combination With CDK4/6 Inhibitor Palbociclib in Patients With Advanced or Metastatic Solid Tumors
A Phase 1b/2, Open Label, Dose Escalation and Expansion Study of the Glutaminase Inhibitor Telaglenastat (CB-839) in Combination With CDK4/6 Inhibitor Palbociclib in Patients With Advanced or Metastatic Solid Tumors
Enrollment Status: Completed
Publish Date: September 19, 2022
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1 Open-label Dose Escalation Study of CGX1321 in Subjects With Advanced Solid Tumors With Expansion in Advanced Gastrointestinal Tumors and Phase 1b Study of CGX1321 in Combination With Pembrolizumab in Subjects With Advanced Colorectal Cancer or in Combination With Encorafenib + Cetuximab in Subjects With BRAFV600E Mutated Advanced Colorectal Cancer
A Phase 1 Open-label Dose Escalation Study of CGX1321 in Subjects With Advanced Solid Tumors With Expansion in Advanced Gastrointestinal Tumors and Phase 1b Study of CGX1321 in Combination With Pembrolizumab in Subjects With Advanced Colorectal Cancer or in Combination With Encorafenib + Cetuximab in Subjects With BRAFV600E Mutated Advanced Colorectal Cancer
Enrollment Status: Unknown
Publish Date: January 26, 2022
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1 Study of SY-1365, a Selective CDK7 Inhibitor, in Adult Patients With Advanced Solid Tumors
A Phase 1 Study of SY-1365, a Selective CDK7 Inhibitor, in Adult Patients With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: March 09, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-502 in Patients With Advanced Solid Tumors With HER2 Expression
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-502 in Patients With Advanced Solid Tumors With HER2 Expression
Enrollment Status: Terminated
Publish Date: February 01, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1a Open-Label, Dose Escalation Study of the Safety and Pharmacokinetics of OMP-336B11 Administered as a Single Agent to Subjects With Locally Advanced or Metastatic Solid Tumors
A Phase 1a Open-Label, Dose Escalation Study of the Safety and Pharmacokinetics of OMP-336B11 Administered as a Single Agent to Subjects With Locally Advanced or Metastatic Solid Tumors
Enrollment Status: Terminated
Publish Date: August 11, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 8 Less Clinical Trials

119 Total Publications

Fusion Oncoproteins and Cooperating Mutations Define Disease Phenotypes in NUP98-Rearranged Leukemia.
Fusion Oncoproteins and Cooperating Mutations Define Disease Phenotypes in NUP98-Rearranged Leukemia.
Journal: Blood
Published: February 25, 2025
Similar Doctors
Distinguished in Cholangiocarcinoma (Bile Duct Cancer)
Dr. Sukeshi P. Arora
Oncology | Hematology | Hematology Oncology
Distinguished in Cholangiocarcinoma (Bile Duct Cancer)
Dr. Sukeshi P. Arora
Oncology | Hematology | Hematology Oncology

The University Of Texas Health Science Center At San Antonio

7703 Floyd Curl Dr, Suite Mc7977, 
San Antonio, TX 
 (0.4 miles away)
210-450-9000
Languages Spoken:
English, Hindi, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Sukeshi Arora is an Oncologist and a Hematologist in San Antonio, Texas. Dr. Arora is rated as a Distinguished provider by MediFind in the treatment of Cholangiocarcinoma (Bile Duct Cancer). Her top areas of expertise are Colorectal Cancer, Pancreatic Cancer, Cholangiocarcinoma (Bile Duct Cancer), and Familial Pancreatic Cancer. Dr. Arora is currently accepting new patients.

Advanced in Cholangiocarcinoma (Bile Duct Cancer)
Dr. Arun R. Rao
Hematology Oncology | Oncology | Hematology
Advanced in Cholangiocarcinoma (Bile Duct Cancer)
Dr. Arun R. Rao
Hematology Oncology | Oncology | Hematology

Texas Oncology PA

3327 Research Plz, Suite 102, 
San Antonio, TX 
 (14.2 miles away)
210-337-4494
Languages Spoken:
English, Hindi, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Arun Rao is a Hematologist Oncology specialist and an Oncologist in San Antonio, Texas. Dr. Rao is rated as a Distinguished provider by MediFind in the treatment of Cholangiocarcinoma (Bile Duct Cancer). His top areas of expertise are Gastroesophageal Junction Cancer, Familial Colorectal Cancer, Lynch Syndrome, and Colorectal Cancer. Dr. Rao is currently accepting new patients.

Experienced in Cholangiocarcinoma (Bile Duct Cancer)
Dr. Gopichand B. Pendurti
Hematology Oncology | Hematology | Oncology
Experienced in Cholangiocarcinoma (Bile Duct Cancer)
Dr. Gopichand B. Pendurti
Hematology Oncology | Hematology | Oncology

South Texas Oncology And Hematology, PLLC

4383 Medical Dr, 
San Antonio, TX 
 (0.1 miles away)
210-593-5700
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Gopichand Pendurti is a Hematologist Oncology specialist and a Hematologist in San Antonio, Texas. Dr. Pendurti is rated as a Distinguished provider by MediFind in the treatment of Cholangiocarcinoma (Bile Duct Cancer). His top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Lynch Syndrome, Bone Marrow Aspiration, and Splenectomy. Dr. Pendurti is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Papadopoulos's expertise for a condition
ConditionClose
      View All 17 Advanced Conditions
      View All 26 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile